DK2742019T3 - N1-cyklisk amin-n5-substituerede phenylbiguanidderivater og farmaceutisk sammensætning, der omfatter disse - Google Patents
N1-cyklisk amin-n5-substituerede phenylbiguanidderivater og farmaceutisk sammensætning, der omfatter disse Download PDFInfo
- Publication number
- DK2742019T3 DK2742019T3 DK12821403.8T DK12821403T DK2742019T3 DK 2742019 T3 DK2742019 T3 DK 2742019T3 DK 12821403 T DK12821403 T DK 12821403T DK 2742019 T3 DK2742019 T3 DK 2742019T3
- Authority
- DK
- Denmark
- Prior art keywords
- derivatives
- pharmaceutical composition
- composition including
- phenylbiguanide
- substituted
- Prior art date
Links
- 239000008194 pharmaceutical composition Chemical class 0.000 title 1
- 150000004288 phenylbiguanides Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
- C07C279/24—Y being a hetero atom
- C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20110078764 | 2011-08-08 | ||
| KR20110089272 | 2011-09-02 | ||
| PCT/KR2012/006326 WO2013022278A2 (en) | 2011-08-08 | 2012-08-08 | N1-cyclic amine-n5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2742019T3 true DK2742019T3 (da) | 2021-05-25 |
Family
ID=47669085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12821403.8T DK2742019T3 (da) | 2011-08-08 | 2012-08-08 | N1-cyklisk amin-n5-substituerede phenylbiguanidderivater og farmaceutisk sammensætning, der omfatter disse |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9540325B2 (da) |
| EP (1) | EP2742019B1 (da) |
| JP (1) | JP5927518B2 (da) |
| KR (1) | KR101425061B1 (da) |
| CN (1) | CN103827083B (da) |
| DK (1) | DK2742019T3 (da) |
| ES (1) | ES2869423T3 (da) |
| WO (1) | WO2013022278A2 (da) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102034899B1 (ko) * | 2013-02-07 | 2019-10-22 | 이뮤노메트테라퓨틱스 인코포레이티드 | Ν1-고리아민-ν5-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
| ES2797574T3 (es) | 2013-02-07 | 2020-12-02 | Immunomet Therapeutics Inc | Derivados de biguanida N1-cíclica amina-N5-sustituida, métodos de preparación de la misma y composición farmacéutica que comprende la misma |
| KR102088001B1 (ko) * | 2013-05-23 | 2020-03-12 | 이뮤노메트테라퓨틱스 인코포레이티드 | N1-고리아민-n5-치환된 바이구아나이드 유도체를 유효성분으로 함유하는 섬유화 예방 또는 치료용 약학 조성물 |
| KR102310185B1 (ko) * | 2013-11-04 | 2021-10-12 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
| KR102192726B1 (ko) * | 2013-11-04 | 2020-12-18 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 화합물 및 이의 용도 |
| CN104262205B (zh) * | 2014-09-02 | 2017-04-12 | 浙江工业大学 | N‑芳基双胍氢碘酸盐类化合物及其制备方法和应用 |
| CN104230760B (zh) * | 2014-09-02 | 2016-07-06 | 浙江工业大学 | N-芳基取代的双胍氢溴酸盐类化合物及制备方法和应用 |
| KR102364358B1 (ko) * | 2015-04-30 | 2022-02-17 | 이뮤노메트테라퓨틱스 인코포레이티드 | 구아니딘 화합물 및 이의 용도 |
| KR102253478B1 (ko) * | 2015-05-13 | 2021-05-20 | 이뮤노메트테라퓨틱스 인코포레이티드 | 바이구아나이드 유도체를 유효성분으로 포함하는 교모세포종 예방 또는 치료용 의약 조성물 |
| WO2017093912A1 (en) * | 2015-11-30 | 2017-06-08 | Glaxosmithkline Intellectual Property (No.2) Limited | Formulations for intravenous injection of danirixin |
| TWI680122B (zh) * | 2016-09-07 | 2019-12-21 | 國立陽明大學 | 活化腺苷單磷酸活化蛋白激酶之化合物 |
| US10344002B2 (en) | 2016-09-26 | 2019-07-09 | Nusirt Sciences, Inc. | Compositions and methods for treating metabolic disorders |
| KR20180087189A (ko) * | 2017-01-24 | 2018-08-01 | 연세대학교 산학협력단 | 염증성 질환, 자가면역 질환, 또는 이들의 조합을 예방 또는 치료하기 위한 약학적 조성물 및 이를 이용한 방법 |
| US20190046478A1 (en) * | 2017-08-10 | 2019-02-14 | The Royal Institution For The Advancement Of Learning/Mcgill University | Biological marker for identifying cancer patients for treatment with a biguanide |
| EP3700512A4 (en) | 2017-10-24 | 2021-08-11 | Lunella Biotech, Inc. | MITOFLAVOSCINE: TARGETING FLAVINAL ENZYMES ELIMINATES CANCER STEM CELLS (CSCS) BY INHIBITING MITOCHONDRIAL BREATHING |
| EP3969444A4 (en) * | 2019-05-13 | 2023-10-18 | The Regents of the University of California | COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISEASES AND DISORDERS |
| CN110357795B (zh) * | 2019-07-26 | 2021-10-29 | 湖南师范大学 | 一种双胍衍生物、药物组合物、制备方法和其在制备抗肿瘤药物中的应用 |
| CN110615886A (zh) * | 2019-09-05 | 2019-12-27 | 哈尔滨工程大学 | 一种双胍衍生物抗菌型环氧树脂固化剂及其制备方法 |
| KR102552913B1 (ko) * | 2019-12-02 | 2023-07-07 | 주식회사 하임바이오 | 알데히드 억제제 및 비구아나이드 계열 화합물을 포함하는 속발성 암의 예방 및 치료용 약학조성물 |
| WO2023278300A1 (en) * | 2021-06-28 | 2023-01-05 | ImmunoMet Therapeutics, Inc. | Solid dosage form of n-1-pyrrolidine-n-5-(3-trifluoromethoxy)phenyl biguanide and uses thereof |
| CN114671830A (zh) * | 2022-04-24 | 2022-06-28 | 西安石油大学 | 一种双胍衍生物盐酸盐的制备方法 |
| CN115261355B (zh) * | 2022-09-14 | 2023-07-28 | 广东医科大学 | AMPKα1琥珀酰化修饰及应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2467371A (en) * | 1944-05-10 | 1949-04-19 | Ici Ltd | Biguanide derivatives |
| GB599714A (en) * | 1945-10-08 | 1948-03-18 | Robert De Brath Ashworth | Manufacture of biguanide derivatives |
| FR6786M (da) | 1967-08-10 | 1969-03-17 | ||
| US3960949A (en) | 1971-04-02 | 1976-06-01 | Schering Aktiengesellschaft | 1,2-Biguanides |
| FR2809310B1 (fr) * | 2000-05-26 | 2004-02-13 | Centre Nat Rech Scient | Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant |
| KR100772531B1 (ko) | 2001-06-30 | 2007-11-01 | 주식회사 하이닉스반도체 | 캐패시터의 제조 방법 |
| HUP0300990A2 (hu) | 2003-04-15 | 2005-05-30 | SynoSens Kutató és Fejlesztő Kft. | Szinergista gyógyszer-kombináció a diabetesz megelőzésére vagy kezelésére |
| CN1846694B (zh) | 2005-04-12 | 2012-02-01 | 中国医学科学院血液学研究所 | 取代芳香基双胍类化合物及含它们的药物组合物在制备抗恶性肿瘤药物方面的应用 |
| US20110263901A1 (en) | 2008-01-23 | 2011-10-27 | Dhananjay Govind Sathe | Process of Preparation of Proguanil |
| KR101136045B1 (ko) * | 2009-11-16 | 2012-04-18 | 한국화학연구원 | N1-(펜에틸)-n2-치환된 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
| WO2011083998A2 (ko) * | 2010-01-06 | 2011-07-14 | 한올바이오파마주식회사 | 바이구아나이드 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 약학 조성물 |
-
2012
- 2012-08-08 JP JP2014524932A patent/JP5927518B2/ja active Active
- 2012-08-08 ES ES12821403T patent/ES2869423T3/es active Active
- 2012-08-08 US US14/237,514 patent/US9540325B2/en active Active
- 2012-08-08 KR KR1020120086999A patent/KR101425061B1/ko active Active
- 2012-08-08 DK DK12821403.8T patent/DK2742019T3/da active
- 2012-08-08 CN CN201280038931.XA patent/CN103827083B/zh active Active
- 2012-08-08 WO PCT/KR2012/006326 patent/WO2013022278A2/en not_active Ceased
- 2012-08-08 EP EP12821403.8A patent/EP2742019B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013022278A3 (en) | 2013-04-25 |
| KR20130019351A (ko) | 2013-02-26 |
| CN103827083B (zh) | 2016-03-09 |
| EP2742019B1 (en) | 2021-03-03 |
| JP5927518B2 (ja) | 2016-06-01 |
| ES2869423T3 (es) | 2021-10-25 |
| EP2742019A4 (en) | 2015-01-07 |
| US9540325B2 (en) | 2017-01-10 |
| WO2013022278A2 (en) | 2013-02-14 |
| JP2014524424A (ja) | 2014-09-22 |
| EP2742019A2 (en) | 2014-06-18 |
| KR101425061B1 (ko) | 2014-08-06 |
| US20140179660A1 (en) | 2014-06-26 |
| CN103827083A (zh) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2742019T3 (da) | N1-cyklisk amin-n5-substituerede phenylbiguanidderivater og farmaceutisk sammensætning, der omfatter disse | |
| DK3415157T3 (da) | N-acyldipeptidderivater og anvendelser deraf | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| DK2729151T3 (da) | Farmaceutisk sammensætning, fremgangsmåder til behandling og anvendelser deraf | |
| DK2694038T3 (da) | Farmaceutisk sammensætning | |
| DK2920167T3 (da) | Hydrazinyl-indol-forbindelser og konjugater | |
| IL230662A0 (en) | Indazoles | |
| BR112014012005A2 (pt) | composições, métodos, formulação farmacêutica e artigo | |
| PL2793600T3 (pl) | Topliwa bezdymna kompozycja tytoniowa | |
| BR112013014644A2 (pt) | composição farmacêutica e complexo | |
| DK3366143T3 (da) | Probiotiske sammensætninger og fremgangsmåder | |
| DK2861223T3 (da) | Sammensætninger og metoder til transmukosal absorption | |
| DK2745849T3 (da) | Polydeoxyribonukleotidsammensætning og anvendelser deraf | |
| BR112014010290A2 (pt) | composição farmacêutica, métodos, composições e usos | |
| IL238825B (en) | The history of heterocyclics, their preparation and pharmaceutical preparations containing them | |
| BR112014009889A2 (pt) | compostos dissubstituídos, compostos e composição farmacêutica | |
| IL232217A (en) | Derivatives of Azul, pharmaceutical preparations containing them and their use | |
| DK2917181T3 (da) | Heteroarylderivater og anvendelser deraf | |
| HUE044521T2 (hu) | Görögdinnye szilárdságával kapcsolatos eljárások és kompozíciók | |
| PT2706062T (pt) | Novos derivados da cefalosporina e sua composição farmacêutica | |
| DK2704744T3 (da) | Komplementfaktor-b-analoger og anvendelser deraf | |
| DK2897594T3 (da) | Farmaceutisk sammensætning | |
| DK3156060T3 (da) | Farmaceutiske sammensætninger og topisk anvendelse deraf | |
| DK2802320T3 (da) | Tricykliske forbindelser, sammensætninger omfattende disse og anvendelser deraf | |
| BR112013022306A2 (pt) | método, e, composição |